Clinical Scorecard: Consensus Guidelines on Long-Acting Growth Hormone Treatment for Pediatric Patients with Growth Hormone Deficiency
At a Glance
Category
Detail
Condition
Pediatric Growth Hormone Deficiency
Key Mechanisms
Use of long-acting growth hormone (LAGH) formulations to reduce injection frequency and treatment burden compared to daily GH injections
Target Population
Children with growth hormone deficiency, including treatment-naïve and treatment-experienced patients
Care Setting
Pediatric endocrinology clinical practice with access to LAGH therapies approved in multiple countries
Key Highlights
LAGH therapies (lonapegsomatropin, somapacitan, somatrogon) have demonstrated noninferiority to daily GH in phase III trials.
LAGH offers potential advantages including reduced injection frequency, improved adherence, and decreased treatment burden.
Current data on LAGH in pediatric GH deficiency are mostly from clinical trials; long-term real-world data are lacking.
Guideline-Based Recommendations
Diagnosis
Confirm diagnosis of pediatric growth hormone deficiency before initiating LAGH therapy.
Consider patient selection carefully, including treatment-naïve and those switching from daily GH.
Management
Initiate LAGH therapy using formulations with international regulatory approval and phase III trial evidence.
Adjust doses based on clinical response and growth parameters.
Educate patients and caregivers on administration techniques and adherence importance.
Monitoring & Follow-up
Regularly monitor growth velocity and IGF-1 levels to guide dose adjustments.
Assess adherence and injection technique at follow-up visits.
Monitor for adverse effects as per standard GH therapy protocols.
Risks
Potential unknown long-term safety risks due to limited real-world data.
Risk of nonadherence remains but may be reduced with LAGH.
Consider individual patient factors and preferences to minimize treatment burden.
Patient & Prescribing Data
Children with confirmed growth hormone deficiency, including those previously treated with daily GH and treatment-naïve patients.
Patients and caregivers show strong preference for LAGH due to reduced injection frequency and perceived lower treatment burden, which may improve adherence and outcomes.
Clinical Best Practices
Use LAGH formulations with robust phase III trial data and regulatory approval in multiple countries.
Engage patients and caregivers in shared decision-making regarding treatment options.
Provide thorough education on LAGH administration and adherence importance.
Monitor growth response and IGF-1 levels regularly to optimize dosing.
Recognize current knowledge gaps and the need for long-term real-world data.
by Aristides Maniatis, Wayne Cutfield, Mehul Dattani, Cheri Deal, Paulo Ferrez Collett-Solberg, Reiko Horikawa, Mohamad Maghnie, Bradley S Miller, Michel Polak, Lars Sävendahl, Joachim Woelfle
